NovaBridge Biosciences names Martin Dewhurst independent director

• NovaBridge Biosciences appointed Martin Dewhurst as an independent director, effective immediately.
• Dewhurst joined the Audit Committee, also took a seat on the Compensation Committee.
• He brings more than 30 years of board and C-suite experience across biotech, biopharma, medical devices, health tech, healthcare investment.
• Independent director Liu Xin departed the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-384355), on September 08, 2026, and is solely responsible for the information contained therein.